ReviewCancers2023
Gastric Cancer: Molecular Mechanisms, Novel Targets, and Immunotherapies: From Bench to Clinical Therapeutics.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 25 citations in OpenAlex.
- Serum levels of immunoglobulins, tumour markers, and chemokines in gastric cancer patients treated with SOX regimen versus oxaliplatin monotherapy.Journal of medical biochemistry · 2026Article
- Exploring the anticancer potential of Streptomyces sp. M4 extract: effects on apoptosis in gastric cancer ags cells.Folia microbiologica · 2026Article
- N-benzylbenzamide derivative (SBM685) as a novel MDR1 inhibitor for overcoming 5 fluorouracil resistance in gastric cancer through computational and in vitro analysis.Discover oncology · 2026Article
- Bioorthogonal catalytic centres engineered for gastrointestinal stabilization provide oral delivery for the treatment of gastric cancer.Journal of nanobiotechnology · 2026Article
- Molecular Mechanisms and Biomarkers Driving the Transition From Chronic Atrophic Gastritis to Gastric Cancer.Clinical Medicine Insights. Oncology · 2026Review
- Young-Onset Gastric Cancer: Clinical and Genetic Perspectives.Journal of gastric cancer · 2026Review
- A phase separation-related gene signature for prognosis prediction and immunotherapy response evaluation in gastric cancer with targeted natural compound discovery.Discover oncology · 2025Article
- Prevalence of HER2 expression and its association with clinicopathological parameters in gastric and gastroesophageal junction adenocarcinoma: A 10?year experience of an academic center.Molecular and clinical oncology · 2025Article
- Helicobacter pylori and gastric cancer: mechanisms and new perspectives.Journal of hematology & oncology · 2025Review
- Frontiers in thoracic oncology: new breakthroughs in molecular targets and immunotherapy.Frontiers in immunology · 2025Review
- Metformin and its Nanoformulations in Cancer Prevention and Therapy.Current pharmaceutical design · 2025Review
- Ferroptosis and gastric cancer: from molecular mechanisms to clinical implications.Frontiers in immunology · 2025Review
- SBL-JP-0004: A promising dual inhibitor of JAK2 and PI3KCD against gastric cancer.Oncology research · 2025Article
- A Comprehensive Review on Novel Pathways in Cancer Treatment: Clinical Applications and Future Prospects.Current cancer drug targets · 2025Review
- Prognostic Influence of Galectin-1 in Gastric Adenocarcinoma.Biomedicines · 2024Article
- In silico analysis unveiling potential biomarkers in gallbladder carcinogenesis.Scientific reports · 2024Article
- ECHDC2 inhibits the proliferation of gastric cancer cells by binding with NEDD4 to degrade MCCC2 and reduce aerobic glycolysis.Molecular medicine (Cambridge, Mass.) · 2024Article
- PCAT19: the role in cancer pathogenesis and beyond.Frontiers in cell and developmental biology · 2024Review
- Predicting early gastric cancer risk using machine learning: A population-based retrospective study.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer is a global health concern, ranking fifth in cancer diagnoses and fourth in cancer-related deaths worldwide. Despite recent advancements in diagnosis, most cases are detected at advanced stages, resulting in poor outcomes. However, recent breakthroughs in genome analysis have identified biomarkers that hold positive clinical significance for GC treatment. These biomarkers and classifications offer the potential for more precise diagnostic and therapeutic approaches for GC patients. In this review, we explore the classification and molecular pathways in this disease, highlighting potential biomarkers that have emerged in recent studies including targeted therapies and immunotherapies. These advancements provide a promising direction for improving the management of GC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.